Olema Pharmaceuticals (OLMA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.61
- Estimate
- -$0.56
- Surprise
- -8.2%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Olema Pharmaceuticals (OLMA) reported a wider loss than forecast — diluted EPS of -$0.61 against the -$0.56 estimate (a 8.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates OLMA Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -8.2% surprise compares with a -2.0% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: palazestrant
- DATA_ISSUE: analyst_target_implausible (raw $39.30 vs price $10.75 — ratio 3.7×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.86
- Price target
- $11.96
- Stop
- $10.00
- Upside to target
- +10.1%
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
OLMA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $940.6M
- P/E (fwd)
- -4.0
- 52-week range
- $6.65–$36.26
- Off 52-week high
- 70.0%
- RSI (14)
- 50
- Volume vs avg
- 0.52×
- Score today
- 4.6/10